Patent ID: 11879010
Assignee: THE CHARLOTTE MECKLENBURG HOSPITAL AUTHORITY
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 1:
2. A method of delivering a natural killer (NK) cell to a cancer cell in a subject having, suspected of having, or at risk of having cancer, the method comprising:
(a) contacting the cancer cell with a first antibody or fragment thereof, wherein the first antibody or fragment thereof comprises a first antigen binding portion and a targeting ligand and wherein the cancer cell comprises a first antigen on the surface of the cancer cell, wherein the first antigen is CD20, the first antigen binding portion is a CD20 binding portion, and the targeting ligand is tetrazine and wherein the first antigen binding portion of the first antibody or fragment thereof binds the CD20 on the surface of the cancer cell; and
(b) contacting the cancer cell of step (a) with a NK cell comprising a targeting agent specific for the targeting ligand of the first antibody or fragment thereof, wherein the targeting agent is trans-cyclooctene (TCO) and binds in vivo to the targeting ligand of the first antibody or fragment thereof,
thereby delivering the NK cell to the cancer cell in the subject having, suspected of having, or at risk of having cancer.